Atamparib in Patients With Advanced Solid Tumors

Summary

This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).

Timeline

Start

2026-02-10

Primary completion

2028-07-31

Completion

2029-01-31

Drugs

Indications